Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach

A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of... IntroductionThe purpose of this study was to evaluate the absolute bioavailability (BA) of AG-221 following a single oral dose of 100 mg AG-221 and an intravenous (IV) dose of ~ 100 μg AG-221 containing approximately 300 nCi of [14C]-AG-221.MethodsThis was a phase 1, open-label study. Six subjects who met all of the inclusion criteria and none of the exclusion criteria were enrolled in the study. After an overnight fast of at least 10 h, the subjects received an oral dose (coated tablet) of 100 mg of AG-221 at 0 h on dosing day. Four hours after the oral dose, the subjects received 100 μg AG-221 containing ~ 300 nCi of [14C]-AG-221 administered as an IV bolus. Blood samples were collected and analyzed for plasma concentrations of AG-221 and [14C]-AG-221 using a validated liquid chromatography with tandem mass spectrometry (LC–MS/MS) system and high-performance liquid chromatography (HPLC) fractionation followed by accelerator mass spectrometry analysis (AMS), respectively. Safety was evaluated throughout the study.ResultsThe absolute BA after a 100-mg oral dose of AG-221 was measured as 57.2%. While the total clearance was 1.37 L/h, ~ 1/60 of the liver blood flow in a typical 70-kg human subject, the first-pass extraction was estimated to be less than 2%, assuming that the total clearance was entirely due to liver metabolism. Thus, the fraction of the AG-221 dose absorbed was at least 50%. AG-221 was safe and well tolerated when given under fasted conditions in a single 100-mg dose as a coated tablet with a microtracer [14C]-AG-221 solution, as few drug-related treatment-emergent adverse events (TEAEs) were reported. No clinically significant changes or findings were noted in the clinical laboratory evaluations, vital sign measurements, and electrocardiograms (ECGs) performed during this study.ConclusionsIn healthy subjects under fasting conditions, the absolute BA following oral administration of a 100-mg AG-221 tablet was 57.2%. AG-221 was safe and well tolerated in healthy male subjects when administered as a single 100-mg film-coated tablet plus 100 µg [14C]-AG-221 given intravenously.Trial RegistrationClinicalTrials.gov identifier, NCT02443168.FundingCelgene Corporation. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach

Download PDF
12 pages

Loading next page...
 
/lp/springer-journals/a-phase-1-open-label-study-in-healthy-subjects-to-evaluate-the-BvIdfRclkt
Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2019
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-019-0097-7
Publisher site
See Article on Publisher Site

Abstract

IntroductionThe purpose of this study was to evaluate the absolute bioavailability (BA) of AG-221 following a single oral dose of 100 mg AG-221 and an intravenous (IV) dose of ~ 100 μg AG-221 containing approximately 300 nCi of [14C]-AG-221.MethodsThis was a phase 1, open-label study. Six subjects who met all of the inclusion criteria and none of the exclusion criteria were enrolled in the study. After an overnight fast of at least 10 h, the subjects received an oral dose (coated tablet) of 100 mg of AG-221 at 0 h on dosing day. Four hours after the oral dose, the subjects received 100 μg AG-221 containing ~ 300 nCi of [14C]-AG-221 administered as an IV bolus. Blood samples were collected and analyzed for plasma concentrations of AG-221 and [14C]-AG-221 using a validated liquid chromatography with tandem mass spectrometry (LC–MS/MS) system and high-performance liquid chromatography (HPLC) fractionation followed by accelerator mass spectrometry analysis (AMS), respectively. Safety was evaluated throughout the study.ResultsThe absolute BA after a 100-mg oral dose of AG-221 was measured as 57.2%. While the total clearance was 1.37 L/h, ~ 1/60 of the liver blood flow in a typical 70-kg human subject, the first-pass extraction was estimated to be less than 2%, assuming that the total clearance was entirely due to liver metabolism. Thus, the fraction of the AG-221 dose absorbed was at least 50%. AG-221 was safe and well tolerated when given under fasted conditions in a single 100-mg dose as a coated tablet with a microtracer [14C]-AG-221 solution, as few drug-related treatment-emergent adverse events (TEAEs) were reported. No clinically significant changes or findings were noted in the clinical laboratory evaluations, vital sign measurements, and electrocardiograms (ECGs) performed during this study.ConclusionsIn healthy subjects under fasting conditions, the absolute BA following oral administration of a 100-mg AG-221 tablet was 57.2%. AG-221 was safe and well tolerated in healthy male subjects when administered as a single 100-mg film-coated tablet plus 100 µg [14C]-AG-221 given intravenously.Trial RegistrationClinicalTrials.gov identifier, NCT02443168.FundingCelgene Corporation.

Journal

Oncology and Therapy – Springer Journals

Published: Jun 19, 2020

References

  • Enasidenib: first mutant IDH2 inhibitor for the treatment of refractory and relapsed acute myeloid leukemia
    Dogra, R; Bhatia, R; Shankar, R; Bansal, P; Rawal, RK
  • Enasidenib: an oral IDH2 inhibitor for the treatment of acute myeloid leukemia
    Myers, RA; Wirth, S; Williams, S; Kiel, PJ
  • Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
    Pollyea, DA; Tallman, MS; Botton, S; Kantarjian, HM; Collins, R; Stein, AS
  • New Food and Drug Administration-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia
    Click, Zach R.; Seddon, Amanda N.; Bae, Young R.; Fisher, Justin D.; Ogunniyi, Adebayo
  • Recently approved therapies in acute myeloid leukemia: a complex treatment landscape
    Talati, C; Sweet, K
  • Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects
    Li, Yan; Liu, Liangang; Gomez, Diana; Chen, Jian; Tong, Zeen; Palmisano, Maria; Zhou, Simon
  • Absorption, distribution, metabolism and excretion of an isocitrate dehydrogenase-2 inhibitor enasidenib in rats and humans
    Tong, Z; Atsriku, C; Yerramilli, U; Wang, X; Li, Y; Reyes, J
  • Absolute oral bioavailability of glasdegib (PF-04449913), a smoothened inhibitor, in randomized healthy volunteers
    Shaik, N; Hee, B; Liang, Y; LaBadie, RR
  • Simultaneous oral therapeutic and intravenous 14 C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin
    Boulton, David W.; Kasichayanula, Sreeneeranj; Keung, Chi Fung Anther; Arnold, Mark E.; Christopher, Lisa J.; Xu, Xiaohui Sophia; LaCreta, Frank
  • Microdosing and drug development: past, present and future
    Lappin, G; Noveck, R; Burt, T
  • Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development
    Burt, T; Yoshida, K; Lappin, G; Vuong, L; John, C; de Wildt, SN; Sugiyama, Y; Rowland, M
  • Microdosing for reduction of the time and resources for drug development
    Sudo, K
  • Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge
    Ings, RM
  • Phase 0, Including Microdosing Approaches: Applying the Three Rs and Increasing the Efficiency of Human Drug Development
    Burt, Tal; Vuong, Le Thuy; Baker, Elizabeth; Young, Graeme C.; McCartt, A. Daniel; Bergstrom, Mats; Sugiyama, Yuichi; Combes, Robert
  • Absolute Bioavailability of Osimertinib in Healthy Adults
    Vishwanathan, Karthick; So, Karen; Thomas, Karen; Bramley, Alex; English, Stephen; Collier, Jo
  • Novel application of the two-period microtracer approach to determine absolute oral bioavailability and fraction absorbed of ertugliflozin
    Raje, S; Callegari, E; Sahasrabudhe, V; Vaz, A; Shi, H; Fluhler, E
  • Single-dose intravenous safety, tolerability, and pharmacokinetics and absolute bioavailability of LCB01-0371
    Cho, YS; Lim, HS; Han, S; Yoon, SK; Kim, H; Cho, YL